Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MOLNBullishIndustry Newsnews

High materiality8/10

Molecular Partners advances MP0712 in Phase 1/2a; MP0726 imaging and MP0714 expansion

Jul 6, 2026, 1:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive pipeline milestones and upcoming data readouts tend to drive near-term interest in MOLN, especially with cross-listing and strategic collaborations; however, execution risk and data timing remain key constraints.

AI summary

What happened, with direct paths to the underlying reporting

Molecular Partners reports progress across its Radio-DARPin pipeline, led by MP0712 in US Phase 1/2a. Initial data are expected in coming months, with broader efficacy data in 2027. The company also advances MP0726 for mesothelin and MP0714 via compassionate use in South Africa, signaling potential broader deployment of isotope-agnostic radiopharmaceuticals and multiple near-term catalysts.

MP0712 Phase 1/2a dosing underway; DLL3-targeted with Lead-212 payload.
Initial data expected in coming months; comprehensive efficacy data due 2027.
MP0714 compassionate-care program in SA using 225Ac demonstrates isotope versatility.
FIH imaging for MP0726 targeting MSLN planned in H2 2026.
Two INDs planned in 2027; new target nomination in H2 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Molecular Partners advances MP0712 in Phase 1/2a; MP0726 imaging and MP0714 expansion

Molecular Partners to cut workforce by a quarter